RT Journal Article
SR Electronic
T1 Nucleocapsid antigenemia is a marker of acute SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.23.22269354
DO 10.1101/2022.01.23.22269354
A1 Verkerke, Hans P.
A1 Damhorst, Gregory L.
A1 Graciaa, Daniel S.
A1 McLendon, Kaleb
A1 O’Sick, William
A1 Robichaux, Chad
A1 Cheedarla, Narayanaiah
A1 Potlapalli, Sindhu
A1 Wu, Shang-Chuen
A1 Harrington, Kristin R.V.
A1 Webster, Andrew
A1 Kraft, Colleen
A1 Rostad, Christina A.
A1 Waggoner, Jesse J.
A1 Gandhi, Neel R.
A1 Guarner, Jeannette
A1 Auld, Sara C.
A1 Neish, Andrew
A1 Roback, John D.
A1 Lam, Wilbur A.
A1 Shah, N. Sarita
A1 Stowell, Sean R.
YR 2022
UL http://medrxiv.org/content/early/2022/01/27/2022.01.23.22269354.abstract
AB Background Reliable detection of SARS-CoV-2 infection is essential for diagnosis and treatment of disease as well as infection control and prevention during the ongoing COVID-19 pandemic. Existing nucleic acid tests do not reliably distinguish acute from resolved infection, as residual RNA is frequently detected in the absence of replication-competent virus. We hypothesized that viral nucleocapsid in serum or plasma may be a specific biomarker of acute infection that could enhance isolation and treatment strategies at an individualized level.Methods Samples were obtained from a retrospective serological survey using a convenience sampling method from adult inpatient and outpatient encounters from January through March 2021. Samples were categorized along a timeline of infection (e.g. acute, late presenting, convalescent) based on timing of available SARS-CoV-2 testing and symptomatology. Nucleocapsid was quantified by digital immunoassay on the Quanterix HD-X platform.Results In a large sample of 1860 specimens from 1607 patients, the highest level and frequency of antigenemia were observed in samples obtained during acute SARS-CoV-2 infection. Levels of antigenemia were highest in samples from seronegative individuals and in those with more severe disease. Using ROC analysis, we found that antigenemia exhibited up to 85.8% sensitivity and 98.6% specificity as a biomarker for acute COVID-19.Conclusions Nucleocapsid antigenemia is a sensitive and specific biomarker for acute SARS-CoV-2 infection and may aid in individualized assessment of SARS-CoV-2 infection resolution or persistence, although interpretation is limited by absence of a diagnostic gold standard for active infection.Competing Interest StatementC.A.R. institution has received funds to conduct clinical research unrelated to this manuscript from BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc. All other authors report no conflicts of interest. Funding StatementThis work was supported by funds from the Woodruff Health Sciences Center COVID-19 Center for Urgent Research Engagement (CURE), NIH 1 U54 CA260563-01: Immune regulation of COVID-19 infection in cancer and autoimmunity to JDR, a NIH R01 HL138656 COVID-19 supplement to SRS, and NIH Grants U54 EB027690 03 and UL1TR002378.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Emory University for the use of residual clinical specimens. Written informed consent by the patients was not required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors